MX2023012457A - Compuestos para su uso en el tratamiento de trastornos hiperproliferativos. - Google Patents
Compuestos para su uso en el tratamiento de trastornos hiperproliferativos.Info
- Publication number
- MX2023012457A MX2023012457A MX2023012457A MX2023012457A MX2023012457A MX 2023012457 A MX2023012457 A MX 2023012457A MX 2023012457 A MX2023012457 A MX 2023012457A MX 2023012457 A MX2023012457 A MX 2023012457A MX 2023012457 A MX2023012457 A MX 2023012457A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- hyperproliferative disorders
- compounds
- derivatives
- hyperproliferative
- Prior art date
Links
- 230000003463 hyperproliferative effect Effects 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- ACTKAGSPIFDCMF-UHFFFAOYSA-N 1,3-oxazol-2-amine Chemical class NC1=NC=CO1 ACTKAGSPIFDCMF-UHFFFAOYSA-N 0.000 abstract 1
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La presente invención se refiere a derivados de 2-aminotiazol o 2-aminooxazol o a una sal farmacéuticamente aceptable de los mismos para su uso en el tratamiento de trastornos hiperproliferativos, a un método de tratamiento y/o prevención de trastornos hiperproliferativos usando dichos compuestos y a un subgrupo de dichos derivados que son nuevos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21382343.8A EP4079304A1 (en) | 2021-04-21 | 2021-04-21 | Compounds for use in the treatment of hyperproliferative disorders |
PCT/EP2022/060579 WO2022223704A1 (en) | 2021-04-21 | 2022-04-21 | Compounds for use in the treatment of hyperproliferative disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023012457A true MX2023012457A (es) | 2023-11-22 |
Family
ID=75674747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023012457A MX2023012457A (es) | 2021-04-21 | 2022-04-21 | Compuestos para su uso en el tratamiento de trastornos hiperproliferativos. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20240208998A1 (es) |
EP (2) | EP4079304A1 (es) |
JP (1) | JP2024515705A (es) |
KR (1) | KR20240013112A (es) |
CN (1) | CN117320715A (es) |
AU (1) | AU2022260529A1 (es) |
BR (1) | BR112023021959A2 (es) |
CA (1) | CA3216090A1 (es) |
IL (1) | IL307868A (es) |
MX (1) | MX2023012457A (es) |
WO (1) | WO2022223704A1 (es) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009002933A1 (en) * | 2007-06-22 | 2008-12-31 | Hydra Biosciences, Inc. | Methods and compositions for treating disorders |
-
2021
- 2021-04-21 EP EP21382343.8A patent/EP4079304A1/en not_active Withdrawn
-
2022
- 2022-04-21 JP JP2023564537A patent/JP2024515705A/ja active Pending
- 2022-04-21 EP EP22723682.5A patent/EP4326262A1/en active Pending
- 2022-04-21 WO PCT/EP2022/060579 patent/WO2022223704A1/en active Application Filing
- 2022-04-21 IL IL307868A patent/IL307868A/en unknown
- 2022-04-21 KR KR1020237040063A patent/KR20240013112A/ko unknown
- 2022-04-21 BR BR112023021959A patent/BR112023021959A2/pt unknown
- 2022-04-21 US US18/556,456 patent/US20240208998A1/en active Pending
- 2022-04-21 AU AU2022260529A patent/AU2022260529A1/en active Pending
- 2022-04-21 MX MX2023012457A patent/MX2023012457A/es unknown
- 2022-04-21 CN CN202280035450.7A patent/CN117320715A/zh active Pending
- 2022-04-21 CA CA3216090A patent/CA3216090A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2022260529A1 (en) | 2023-11-09 |
US20240208998A1 (en) | 2024-06-27 |
EP4326262A1 (en) | 2024-02-28 |
BR112023021959A2 (pt) | 2023-12-26 |
CN117320715A (zh) | 2023-12-29 |
CA3216090A1 (en) | 2022-10-27 |
EP4079304A1 (en) | 2022-10-26 |
JP2024515705A (ja) | 2024-04-10 |
WO2022223704A1 (en) | 2022-10-27 |
KR20240013112A (ko) | 2024-01-30 |
IL307868A (en) | 2023-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4331677A3 (en) | Methods of treating feline coronavirus infections | |
PH12018500360A1 (en) | Heteroaryl derivatives as parp inhibitors | |
MX2022002196A (es) | Composición de liberación retardada de niclosamida y uso antiviral de la misma. | |
MX2019006721A (es) | Tratamiento para la colangitis biliar primaria. | |
MX2021006884A (es) | Compuestos y su uso para el tratamiento de la deficiencia de alfa1-antitripsina. | |
MX2021015854A (es) | Composiciones y métodos para tratar trastornos del snc. | |
PH12021550713A1 (en) | Medicament for the treatment of chronic cough | |
PH12019550138A1 (en) | Pharmaceutical combinations for treating cancer | |
PH12018500678A1 (en) | Human plasma kallikrein inhibitors | |
MX2021010122A (es) | Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos. | |
MX2021007247A (es) | Derivados de rapamicina. | |
TN2016000489A1 (en) | Carboxamide derivatives. | |
MX2022002597A (es) | Métodos de tratamiento de la epilepsia usando los métodos. | |
MX2021015770A (es) | Inhibidores macrociclicos de mcl-1. | |
MX2021006011A (es) | Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma. | |
MX2022003585A (es) | Metodos para tratar hiperfenilalaninemia. | |
PH12020551343A1 (en) | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer | |
PH12019500849A1 (en) | Naphthyridinone derivatives and their use inthe treatment of arrhythmia | |
EP4234021A3 (en) | Pharmaceutical composition comprising an adenosine derivative for use in the prevention or treatment of diabetic nephropathy | |
MX2020002630A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta. | |
PH12019501566A1 (en) | Amide compounds and use thereof | |
MX2018011592A (es) | Compuesto que tiene actividad inhibitoria de idh mutante, metodo de preparacion y usos del mismo. | |
NZ772236A (en) | Pharmaceutical combination for use in age-related and/or degenerative diseases | |
MX2019015280A (es) | Composiciones de estatinas y metodos para su uso en el tratamiento de sinucleinopatias. | |
MX2021011986A (es) | Metodos de tratamiento de dolor neuropatico. |